Windecker, Stephan <br/><br/>
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.  [electronic resource] 

 -  Circulation  12 2019 
 - 1921-1932 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.119.043308  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--complications<br/>Aged<br/>Anticoagulants--adverse effects<br/>Aspirin--therapeutic use<br/>Atrial Fibrillation--complications<br/>Cardiovascular Agents--therapeutic use<br/>Combined Modality Therapy<br/>Disease Management<br/>Drug Therapy, Combination<br/>Elective Surgical Procedures<br/>Female<br/>Fibrinolytic Agents--adverse effects<br/>Hemorrhage--chemically induced<br/>Hospitalization<br/>Humans<br/>Male<br/>Middle Aged<br/>Percutaneous Coronary Intervention<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Purinergic P2Y Receptor Antagonists--adverse effects<br/>Pyrazoles--therapeutic use<br/>Pyridones--therapeutic use<br/>Treatment Outcome<br/>Vitamin K--antagonists & inhibitors